The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)
Introduction: Sodium-glucose cotransporter type 2 (SGLT2) inhibitors play a crucial role in type 2 diabetes treatment, exerting effects on proximal tubules to reduce glucose reab-sorption and enhance urinary excretion, offering cardiovascular and renoprotective benefits. This study aims to explore t...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Srpsko lekarsko drustvo
2024-01-01
|
| Series: | Hospital Pharmacology |
| Subjects: | |
| Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2024/2334-94922403483D.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832096586751016960 |
|---|---|
| author | Denda Nikola I. Maletin Nemanja Z. Atanasković Marko B. Vučković Biljana A. Rašković Aleksandar L. |
| author_facet | Denda Nikola I. Maletin Nemanja Z. Atanasković Marko B. Vučković Biljana A. Rašković Aleksandar L. |
| author_sort | Denda Nikola I. |
| collection | DOAJ |
| description | Introduction: Sodium-glucose cotransporter type 2 (SGLT2) inhibitors play a crucial role in type 2 diabetes treatment, exerting effects on proximal tubules to reduce glucose reab-sorption and enhance urinary excretion, offering cardiovascular and renoprotective benefits. This study aims to explore the pharmacodynamic advantages of SGLT2 inhibitors, expanding their therapeutic indications and assessing variations in pharmacological effects among different representatives. Methods: A thorough review of literature from 2000 to 2023 via PubMed focused on SGLT2 inhibitors' pharmacology and clinical impact on T2DM, heart failure, and chronic kidney disease. Twenty relevant studies were analyzed to understand differences between these inhibitors, refining their efficacy and safety profiles. Topic: On May 20, 2024, 16 original human studies examining the effects of SGLT2 inhibitors were found. Additionally, 4 original animal studies investigating the impact of SGLT2 inhibitors on laboratory mice were discovered. Conclusion: SGLT2 inhibitors show promise in improving patients' quality of life and reducing diabetes-related complications. Continuous safety and efficiency monitoring is crucial for optimizing their therapeutic use, given limited data on their long-term safety and comparative effectiveness. |
| format | Article |
| id | doaj-art-5e151dc6d01449a591126b43cf8d1cb2 |
| institution | Kabale University |
| issn | 2334-9492 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Srpsko lekarsko drustvo |
| record_format | Article |
| series | Hospital Pharmacology |
| spelling | doaj-art-5e151dc6d01449a591126b43cf8d1cb22025-02-05T13:12:34ZengSrpsko lekarsko drustvoHospital Pharmacology2334-94922024-01-011131483148910.5937/hpimj2403483D2334-94922403483DThe influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)Denda Nikola I.0Maletin Nemanja Z.1Atanasković Marko B.2Vučković Biljana A.3Rašković Aleksandar L.4https://orcid.org/0000-0001-8439-4630University of Novi Sad, Faculty of Medicine Novi Sad, Department of Pharmacology, Toxicology and Clinical Pharmacology, Novi Sad, SerbiaUniversity of Novi Sad, Faculty of Medicine Novi Sad, Department of Pharmacology, Toxicology and Clinical Pharmacology, Novi Sad, SerbiaUniversity of Novi Sad, Faculty of Medicine Novi Sad, Department of Pharmacology, Toxicology and Clinical Pharmacology, Novi Sad, SerbiaUniversity of Novi Sad, Faculty of Medicine Novi Sad, Department of Pathophysiology and Laboratory Medicine, SerbiaUniversity of Novi Sad, Faculty of Medicine Novi Sad, Department of Pharmacology, Toxicology and Clinical Pharmacology, Novi Sad, SerbiaIntroduction: Sodium-glucose cotransporter type 2 (SGLT2) inhibitors play a crucial role in type 2 diabetes treatment, exerting effects on proximal tubules to reduce glucose reab-sorption and enhance urinary excretion, offering cardiovascular and renoprotective benefits. This study aims to explore the pharmacodynamic advantages of SGLT2 inhibitors, expanding their therapeutic indications and assessing variations in pharmacological effects among different representatives. Methods: A thorough review of literature from 2000 to 2023 via PubMed focused on SGLT2 inhibitors' pharmacology and clinical impact on T2DM, heart failure, and chronic kidney disease. Twenty relevant studies were analyzed to understand differences between these inhibitors, refining their efficacy and safety profiles. Topic: On May 20, 2024, 16 original human studies examining the effects of SGLT2 inhibitors were found. Additionally, 4 original animal studies investigating the impact of SGLT2 inhibitors on laboratory mice were discovered. Conclusion: SGLT2 inhibitors show promise in improving patients' quality of life and reducing diabetes-related complications. Continuous safety and efficiency monitoring is crucial for optimizing their therapeutic use, given limited data on their long-term safety and comparative effectiveness.https://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2024/2334-94922403483D.pdfdiabetes mellitussglt2 inhibitorsdiabetic complications 1483 |
| spellingShingle | Denda Nikola I. Maletin Nemanja Z. Atanasković Marko B. Vučković Biljana A. Rašković Aleksandar L. The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) Hospital Pharmacology diabetes mellitus sglt2 inhibitors diabetic complications 1483 |
| title | The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) |
| title_full | The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) |
| title_fullStr | The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) |
| title_full_unstemmed | The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) |
| title_short | The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) |
| title_sort | influence of the pharmacodynamic properties of drugs on indications for their use sodium glucose cotransporter 2 inhibitors sglt2 inhibitors |
| topic | diabetes mellitus sglt2 inhibitors diabetic complications 1483 |
| url | https://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2024/2334-94922403483D.pdf |
| work_keys_str_mv | AT dendanikolai theinfluenceofthepharmacodynamicpropertiesofdrugsonindicationsfortheirusesodiumglucosecotransporter2inhibitorssglt2inhibitors AT maletinnemanjaz theinfluenceofthepharmacodynamicpropertiesofdrugsonindicationsfortheirusesodiumglucosecotransporter2inhibitorssglt2inhibitors AT atanaskovicmarkob theinfluenceofthepharmacodynamicpropertiesofdrugsonindicationsfortheirusesodiumglucosecotransporter2inhibitorssglt2inhibitors AT vuckovicbiljanaa theinfluenceofthepharmacodynamicpropertiesofdrugsonindicationsfortheirusesodiumglucosecotransporter2inhibitorssglt2inhibitors AT raskovicaleksandarl theinfluenceofthepharmacodynamicpropertiesofdrugsonindicationsfortheirusesodiumglucosecotransporter2inhibitorssglt2inhibitors AT dendanikolai influenceofthepharmacodynamicpropertiesofdrugsonindicationsfortheirusesodiumglucosecotransporter2inhibitorssglt2inhibitors AT maletinnemanjaz influenceofthepharmacodynamicpropertiesofdrugsonindicationsfortheirusesodiumglucosecotransporter2inhibitorssglt2inhibitors AT atanaskovicmarkob influenceofthepharmacodynamicpropertiesofdrugsonindicationsfortheirusesodiumglucosecotransporter2inhibitorssglt2inhibitors AT vuckovicbiljanaa influenceofthepharmacodynamicpropertiesofdrugsonindicationsfortheirusesodiumglucosecotransporter2inhibitorssglt2inhibitors AT raskovicaleksandarl influenceofthepharmacodynamicpropertiesofdrugsonindicationsfortheirusesodiumglucosecotransporter2inhibitorssglt2inhibitors |